Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago

Indications

Rheumatoid Arthritis: Tofatin XR is used to treat adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It can be used alone or together with methotrexate or other nonbiologic disease modifying antirheumatic drugs (DMARDs). Psoriatic Arthritis: Tofatin XR is used to treat adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease modifying antirheumatic drugs (DMARDs). Ulcerative Colitis: Tofatin XR is used to treat adult patients with moderately to severely active ulcerative colitis (UC).

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Rheumatoid arthritis is an autoimmune disease marked by dysregulated pro-inflammatory cytokines, including IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta. (3) Signalling by these cytokines leads to tissue inflammation and joint damage by driving the recruitment and activation of immune cells through the janus kinase pathway. Tofacitinib is a partial, reversible janus kinase (JAK) inhibitor that keeps the body from responding to these cytokine signals. By inhibiting JAKs, tofacitinib blocks the phosphorylation and activation of STATs, the proteins that carry the signal onward. The JAK-STAT pathway governs the transcription of genes involved in blood cell formation and immune cell function, so by blocking this pathway, tofacitinib lowers the inflammatory response, which is how it works therapeutically. That said, some evidence suggests it may also act through other pathways.

Pregnancy & Breastfeeding

Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Rheumatoid Arthritis: The usual dose is Tofacitinib 5 mg twice daily, or Tofacitinib 11 mg once daily. For patients with moderate to severe renal impairment or moderate hepatic impairment, the recommended dose is Tofacitinib 5 mg once daily. Psoriatic Arthritis (used together with nonbiologic DMARDs): The usual dose is Tofacitinib 5 mg twice daily, or Tofacitinib 11 mg once daily. For patients with moderate to severe renal impairment or moderate hepatic impairment, the recommended dose is Tofacitinib 5 mg once daily. Ulcerative Colitis: The usual dose is Tofacitinib 10 mg twice daily for at least 8 weeks, followed by 5 mg or 10 mg twice daily. If adequate therapeutic benefit is not achieved, the 10 mg twice daily dose should be discontinued after 16 weeks. The lowest effective dose should be used to maintain response.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.